Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

64
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
64
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.8K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.3K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.3K
The Placebo Effect01:54

The Placebo Effect

6.5K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.5K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

102
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
102
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

542
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
542

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England.

PloS one·2026
Same author

Interventions to address empathy-based stress in mental health workers: A scoping review and research agenda.

PloS one·2024
Same author

Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation.

Health technology assessment (Winchester, England)·2024
Same author

Risk of death in England following a positive SARS-CoV-2 test: A retrospective national cohort study (March 2020 to September 2022).

PloS one·2024
Same author

Common outpatient diagnoses and associated treatments logged by osteopathic medical students within a geriatric population.

Journal of osteopathic medicine·2024
Same author

The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis.

The Lancet regional health. Europe·2024

Related Experiment Video

Updated: Nov 8, 2025

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.3K

Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials.

Clarissa Bauer-Staeb1, Daphne-Zacharenia Kounali2, Nicky J Welton2

  • 1Department of Psychology, University of Bath, Bath, United Kingdom.

Journal of Clinical Epidemiology
|April 23, 2021
PubMed
Summary

This study introduces a new method to determine the minimal clinically important difference (MCID) for depression and anxiety, accounting for individual baseline severity. The findings enable tailored MCID estimates for better clinical practice and treatment evaluation.

Keywords:
Clinically Meaningful ChangeGAD-7MCIDMinimal Clinically Important DifferencePHQ-9Primary Care

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.8K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.7K

Related Experiment Videos

Last Updated: Nov 8, 2025

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.3K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.8K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.7K

Area of Science:

  • Psychiatry and Mental Health
  • Clinical Psychology
  • Health Outcomes Research

Background:

  • Existing minimal clinically important difference (MCID) research for depression and anxiety often relies on population averages.
  • This limitation overlooks the variability in patient experiences and treatment responses based on initial symptom severity.

Purpose of the Study:

  • To determine the MCID for depression and anxiety across a spectrum of baseline severity.
  • To develop a more precise and individualized approach to measuring clinically meaningful change in mental health.

Main Methods:

  • Utilized secondary data from two randomized controlled trials for depression (n=1,122).
  • Calibrated the Global Rating of Change with the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales.
  • Defined MCID using the Effective Dose 50 (ED50) method, representing a 50% probability of patients feeling better relative to their baseline severity.

Main Results:

  • MCID estimates varied significantly with baseline severity.
  • For the PHQ-9, MCID ranged from no change in very mild cases to 14 points (52%) in very severe cases.
  • For the GAD-7, MCID ranged from no change in very mild cases to 10 points (48%) in very severe cases.
  • Average MCID estimates were 3.7 points (23%) for PHQ-9 and 3.3 points (28%) for GAD-7.

Conclusions:

  • The Effective Dose 50 (ED50) method provides more precise MCID estimates across the full range of baseline severity.
  • This approach offers greater precision than population average estimates, albeit with increased complexity.
  • These findings are crucial for tailoring treatment evaluations and clinical practice by adjusting MCID based on specific patient populations and their baseline severity.